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Schuijt, Martin P., Munesh Basdew, Richard van
Veghel, Rene´ de Vries, Pramod R. Saxena, Regien G.
Schoemaker, and A. H. Jan Danser. AT2 receptor-medi-
ated vasodilation in the heart: effect of myocardial infarction.
Am J Physiol Heart Circ Physiol 281: H2590–H2596,
2001.—To investigate the functional consequences of postin-
farct cardiac angiotensin (ANG) type 2 (AT2) receptor upregu-
lation, rats underwent coronary artery ligation or sham opera-
tion and were infused with ANG II 3–4 wk later, when scar
formation is complete. ANG II increased mean arterial pressure
(MAP) more modestly in infarcted animals than in sham ani-
mals. The AT1 receptor antagonist irbesartan, but not the AT2
receptor antagonist PD123319, decreased MAP and antago-
nized the ANG II-mediated systemic hemodynamic effects.
Myocardial (MVC) but not renal vascular conductance (RVC)
was diminished in infarcted versus sham rats. ANG II did not
affect MVC and reduced RVC in all rats. MVC was unaffected
by irbesartan and PD123319 in all animals. However, with
PD123319, ANG II reduced MVC in sham but not infarcted
animals, and, with irbesartan, ANG II increased MVC in in-
farcted but not sham animals. Irbesartan increased RVC and
antagonized the ANG II-mediated renal effects in all ani-
mals. RVC, at baseline or with ANG II, was not affected by
PD123319 in infarcted and sham animals. In conclusion,
coronary but not renal AT2 receptor stimulation results in
vasodilation, and this effect is enhanced in infarcted rats.
angiotensin; heart failure; receptors; vasoconstriction/dila-
tion
THE EFFECTS OF ANGIOTENSIN (ANG) II are mediated by
specific receptors, of which two major receptor sub-
types, termed AT1 and AT2, have been characterized to
date. AT1 receptors mediate essentially all of the
known effects of ANG II, including vasoconstriction
and cell proliferation (37). Much less is known about
the physiological role of AT2 receptors. On the basis of
its high expression in fetal tissues, it has been specu-
lated that AT2 receptors are involved in cell growth
and differentiation (21). Indeed, AT2 receptor stimula-
tion in isolated cells results in growth inhibition and
apoptosis (33, 39, 45), thereby antagonizing the AT1
receptor-mediated growth-stimulatory effects. AT2 re-
ceptor knockout mice are more sensitive to the pressor
action of ANG II than wild-type mice (12, 13), suggest-
ing that AT2 receptors antagonize the AT1 receptor-
mediated rise in blood pressure. However, this increase
in sensitivity may also be explained on the basis of the
increased vascular AT1 receptor expression in AT2 re-
ceptor knockout mice (35). Moreover, AT2 receptor-
mediated blood pressure decreases have not been
found consistently in normal animals (4, 17, 22, 31).
Although initially it was thought that cardiac AT2
receptors disappear after birth, it is now widely ac-
cepted that both AT1 and AT2 receptors are expressed
in the normal adult heart, either at equal levels or with
AT1 receptors predominating (3, 5, 19, 26, 32, 34).
Pathophysiological conditions such as postinfarct re-
modeling and heart failure are accompanied by in-
creased AT2 receptor expression (19, 25, 27, 40, 46)
and/or decreased AT1 receptor expression (2, 11), re-
sulting in a relative AT2 receptor upregulation (23, 26).
Stimulation of cardiac AT2 receptors results in inhibi-
tion of cell growth and fibrillar collagen metabolism,
thereby counteracting the AT1 receptor-mediated ef-
fects on cardiac remodeling after myocardial infarction
(MI) (18, 38). The contribution of AT2 receptors to
coronary blood flow regulation is currently unknown. A
recent study (7) in dogs that underwent a 15-min
coronary artery occlusion followed by 4-h reperfusion
observed an increase in myocardial blood flow after
pretreatment the AT1 receptor antagonist candesar-
tan. This finding is in agreement with the concept that
AT1 and AT2 receptors mediate vasoconstriction and
vasodilation, respectively.
In the present study, we investigated ANG II-medi-
ated effects in the rat coronary circulation in vivo using
the radiolabeled microsphere method. Microspheres
are trapped in end arterioles, thus allowing one to
obtain information on regional hemodynamics by mea-
suring tissue radioactivity. In view of the relative up-
regulation of AT2 receptors after MI, we also studied
the effects of ANG II on coronary blood flow in MI rats.
These studies were performed at 3–4 wk after coronary
ligation, when scar formation is complete (9), i.e., at
the compensated stage of cardiac remodeling (30). Fi-
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nally, for comparison, we investigated ANG II-medi-
ated effects on renal hemodynamics in sham and MI
rats in view of the AT2 receptor-mediated vasodilation
that has been reported in glomerular arterioles (1). All
studies were performed with and without the AT1
receptor antagonist irbesartan or the AT2 receptor an-
tagonist PD123319. The effect of combined AT1 recep-
tor and AT2 receptor blockade was not investigated,
because PD123319 displaces AT1 receptor antagonists
from their plasma protein-binding sites (42–44). Non-
specific displacement of irbesartan would increase its
free (effective) plasma concentration, thereby making
the interpretation of such combination studies highly
complex.
METHODS
The investigation conforms with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals
(NIH Publication No. 85-23, Revised 1996). Experiments
were carried out in male Wistar rats (260–280 g body wt)
obtained from Harlan (Zeist, The Netherlands). Rats were
housed with a 12:12-h light-dark cycle with standard rat
chow and water available at libitum.
Myocardial infarction. Rats were subjected to either
coronary artery ligation (n 5 64) or sham operation (n 5
28). Under pentobarbital sodium (60 mg/kg ip, Apharma;
Arnhem, The Netherlands) anesthesia, the left anterior
descending coronary artery (LADCA) was ligated (30).
Briefly, after the trachea had been intubated, an incision
was made in the skin, and the muscles overlying the fourth
intercostal space were placed aside. The animals were put
on positive pressure ventilation (frequency, 65 breaths/
min; tidal volume, 3 ml), and the thoracic cavity was
opened by cutting the intercostal muscles. The heart was
then carefully pushed to the left, and a 6-0 silk suture was
looped under the LADCA ;2 mm from its origin. After the
heart was returned to its normal position, the suture was
tied. The intercostal space was closed by pulling the ribs
together with 2-0 silk. Subsequently, the muscles were
returned to their normal position, and the skin was su-
tured. Sham-operated animals underwent the same surgi-
cal procedure without the actual LADCA ligation. Proper
occlusion of the LADCA resulted in an extensive transmu-
ral infarction comprising a major part of the left ventric-
ular tissue, with small variations in size (30).
Systemic and regional hemodynamics. At 3–4 wk after
surgery, animals were anesthetized with an intraperitoneal
injection of pentobarbital sodium (60 mg/kg). To maintain an
adequate depth of anesthesia, intravenous bolus injections of
pentobarbital sodium (5–10 mg/kg) were administered via
the right external jugular vein every 15 min during the
stabilization period. A catheter was placed in the trachea for
intermittent positive pressure ventilation with a mixture of
oxygen and air using a respiratory pump (Small Animal
Ventilator, Harvard Apparatus; Natick, MA). The ventilatory
rate was adjusted to keep arterial blood gases within the
physiological range. Blood pressure and heart rate (HR) were
recorded with a pressure transducer (Combitrans Disposable
Pressure Transducer, Braun; Melsungen, Germany) in the
left femoral artery. Radioactive microspheres were injected
into the left ventricle via a catheter in the right carotid
artery. Drugs were administered via the right external jug-
ular vein. The right femoral artery was cannulated to allow
the withdrawal of reference blood samples.
After a 1-h stabilization period after the completion of
instrumentation, animals were given a 30-min infusion of
the AT1 receptor antagonist irbesartan (100
mg z kg21 z min21), the AT2 receptor antagonist PD123319
(20 mg z kg21 z min21, continued throughout the experiment
to ensure blockade) (31), or vehicle (saline, 0.1 ml/min).
Two consecutive 10-min infusions of ANG II (100 and 300
ng z kg21 z min21) were then given to each animal. At the
end of each ANG II infusion, when a steady state had been
reached, hemodynamic parameters were measured, and
the distribution of aortic blood flow was determined by
injecting 15.5 6 0.1 (means 6 SD)-mm-diameter micro-
spheres labeled with 141Ce, 103Ru, or 95Nb (NEN-DuPont;
Boston, MA). For each measurement, ;200,000 micro-
spheres suspended in 0.2 ml of saline and labeled with one
of the isotopes, were mixed, and injected into the left
ventricle over a 15-s period. After each injection, the cath-
eter was thoroughly flushed with 0.5 ml saline. Starting
10 s before microsphere injection and lasting 70 s, an
arterial reference blood sample was drawn from the right
femoral artery at a constant rate of 0.5 ml/min using a
withdrawal pump (model 55, Harvard Apparatus). At the
end of the experiment, the animal was euthanized with an
overdose of pentobarbital, and the heart and kidneys were
removed. The ventricles were separated from atria and
large vessels and subsequently divided into right and left
ventricular tissue and interventricular septum tissue. The
left ventricular tissue of MI hearts was further divided
into viable tissue and scar tissue based on macroscopic
appearance. Tissues were washed thoroughly to remove
radioactive microspheres not trapped in arterioles,
weighed, and put into vials. The radioactivity in the refer-
ence blood samples and tissues was counted for 5 min in a
gamma scintillation counter (Minaxi Auto-Gamma 5000
series, Packard; Downers Grove, IL) using suitable win-
dows, discriminating the different isotopes. Tissues other
than the heart and kidney were also removed and counted,
but because the findings in these tissues resembled those
in the kidney, they will not be discussed here.
Drugs. Irbesartan was the kind gift of Bristol-Myers-
Squibb (Princeton, NJ). PD123319 was the kind gift of Parke-
Davis (Natick, MA). Irbesartan (330 mg/ml) was dissolved in
1.2 mmol/l KOH as described by Trippodo et al. (36).
PD123319 (70 mg/ml) and ANG II (0.33 and 0.99 mg/ml,
respectively) were dissolved in saline.
Data presentation and statistical analysis. Data were pro-
cessed as described previously (28). Cardiac output (CO) and
regional blood flow were calculated as follows
CO 5
amount of radioactivity injected
3 withdrawal rate of arterial blood sample
radioactivity of arterial blood sample
(1)
and
regional blood flow 5
tissue radioactivity 3 CO
amount of radioactivity injected
(2)
Systemic and regional vascular conductances [i.e., CO and
regional blood flow corrected for mean arterial blood pres-
sure (MAP)] were calculated to quantify the vasoconstric-
tor effects of ANG II with or without its receptor antago-
nists.
All data are presented as means 6 SE. Duncan’s new
multiple-range test was used to test differences from baseline
once a two-way ANOVA had revealed that differences existed
between the consecutive infusions. Student’s unpaired t-test
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was used to evaluate the effects of the AT receptor antago-
nists once two-way repeated-measures ANOVA followed by
Bonferroni’s correction had revealed differences between the
groups. To evaluate differences between sham and MI ani-
mals, Student’s unpaired t-test was used. Statistical signifi-
cance was accepted at P , 0.05 (two tailed).
RESULTS
Mortality. All 28 sham animals survived the fol-
lowup period. Three sham animals were excluded from
analysis due to technical failure during microsphere
injection. Of the 64 MI animals, 32 animals died within
24 h after LADCA ligation and 8 animals died due to
technical failure during microsphere injection. Three
MI animals were excluded from analysis because the
infarcted area comprised only a minor part (,20%) of
the left ventricular free wall.
Systemic hemodynamic effects. Acute administration
of irbesartan or PD123319 did not affect CO or HR in
sham and MI animals (Fig. 1). Irbesartan, but not
PD123319, reduced MAP and tended to increase (P 5
not significant) systemic vascular conductance in sham
and MI rats. ANG II reduced systemic vascular con-
ductance similarly in sham and MI animals. ANG II
did not affect HR and reduced CO in MI animals only.
The ANG II-induced rise in MAP was larger in sham
(44 6 6 mmHg) animals than in MI (26 6 5 mmHg)
animals (P , 0.05). In both sham and MI rats, irbesar-
tan reduced or abolished the systemic hemodynamic
effects of ANG II, whereas PD123319 did not affect
these effects.
Cardiac hemodynamic effects. MI reduced left ven-
tricular blood flow by 35% but did not significantly
affect right ventricular, interventricular septal, or
atrial blood flow (Fig. 2). As a consequence, myocardial
blood flow (i.e., the sum of left and right ventricular,
interventricular septal, and atrial blood flow) and myo-
cardial vascular conductance were lower (P , 0.05) in
MI animals than in sham animals (Figs. 2 and 3).
Irbesartan and PD123319 did not affect myocardial
vascular conductance. In sham animals, ANG II, with
or without irbesartan, did not affect myocardial vascu-
lar conductance. Only in the presence of PD123319 did
ANG II infusions decrease myocardial vascular con-
ductance (i.e., caused coronary vasoconstriction) in
sham animals. This effect was due to vasoconstriction
in the left ventricle (Table 1). In MI animals, ANG II
also did not affect myocardial vascular conductance,
nor did PD123319 affect the myocardial vascular re-
sponse to ANG II. In the presence of irbesartan, how-
ever, ANG II increased myocardial vascular conduc-
tance (i.e., caused vasodilation) in MI animals. These
vasodilatory effects were limited to the right ventricle
and the viable part of the left ventricle (Table 1).
Renal hemodynamic effects. MI did not affect renal
vascular conductance (Fig. 3). Irbesartan, but not
PD123319, increased renal vascular conductance. ANG
II decreased renal vascular conductance, and this ef-
fect was reduced or blocked by irbesartan. PD123319
did not affect ANG II-mediated responses in the kid-
ney.
Fig. 1. Effects of 10-min intravenous infusions of angiotensin II on mean
arterial blood pressure (A), heart rate (B), cardiac output (C), and systemic
vascular conductance (D) in sham-operated and myocardial infarcted (MI)
rats pretreated with vehicle (0.1 ml/min, n 5 9 and n 5 7, respectively),
irbesartan (100 mgzkg21zmin21, n 5 8 and n 5 7, respectively), or
PD123319 (20 mgzkg21zmin21, n 5 8 and n 5 7, respectively). Values are
means 6 SE. *P , 0.05 vs. baseline; †P , 0.05 vs. vehicle.
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DISCUSSION
The present study supports the concept of AT2 recep-
tor-mediated vasodilation in the rat coronary vascular
bed. No such vasodilation was observed in the renal
vascular bed or the systemic circulation in either nor-
mal or MI animals.
ANG II infusion into sham-operated rats did not
affect myocardial vascular conductance despite its sig-
nificant pressor effects, thereby indicating either a
balance between AT1 and AT2 receptors in the coronary
circulation in the normal heart or autoregulatory
mechanisms overruling any ANG II-mediated coronary
effects. In support of the first concept, myocardial vas-
cular conductance did decrease (i.e., vasoconstriction
occurred) when ANG II was infused in the presence of
the AT2 receptor antagonist PD123319. These data are
in agreement with studies (3, 41) providing evidence
for the presence of both AT1 and AT2 receptors in
coronary arteries of normal hearts. Remarkably, how-
ever, coronary vasodilation did not occur during ANG
II infusion in the presence of the AT1 receptor antago-
nist irbesartan at a dose that fully prevented the sys-
temic pressor effects of ANG II. This indicates that,
normally, AT2 receptor-mediated coronary vasodila-
tion is of limited importance and mainly serves to
counteract AT1 receptor-mediated effects. This may be
different under pathological conditions, when AT2 re-
ceptors are upregulated (23, 46) relative to AT1 recep-
tors either because AT2 receptor density increases
and/or because AT1 receptor density decreases (2, 11,
19, 23, 25–27, 40). Indeed, 3–4 wk after MI, we ob-
served ANG II-mediated coronary vasodilation in the
presence of irbesartan. In agreement with a reduced
density of AT1 receptors in the infarcted heart, ANG II
did not cause coronary vasoconstriction in the presence
of PD123319. An alternative, less likely, explanation
for this lack of ANG II-mediated vasoconstriction in
the presence of PD123319 is that, due to the upregu-
lation of AT2 receptors in the infarcted heart, the
applied dose of PD123319 was insufficient to obtain full
blockade of cardiac AT2 receptors. Previous studies,
however, have demonstrated that this dose of
PD123319 is sufficient to result in micromolar blood
plasma concentrations (i.e., concentrations that selec-
tively block AT2 receptors) and that higher doses will
lead to concentrations that also interfere with AT1
receptors (20). Moreover, the previously described in-
creases in AT2 receptor density are relatively modest,
i.e., less than three- to fourfold (23, 24).
We were unable to demonstrate a vasodilator role for
AT2 receptors in the systemic circulation and kidney.
The irbesartan-induced increases in systemic and re-
nal vascular conductance in sham-operated and MI
rats are suggestive for AT1 receptor-mediated vasocon-
striction by endogenous ANG II in anesthetized ani-
mals. No PD123319-induced decreases in systemic or
renal vascular conductance were observed in normal or
MI rats, nor did the AT2 receptor antagonist affect the
ANG II-induced systemic and renal hemodynamic re-
sponses in these rats. Thus MI does not appear to
result in AT2 receptor upregulation in organs other
Fig. 3. Effects of 10-min intravenous infusions of angiotensin II on
myocardial (A) and renal vascular conductance (B) in sham-operated
and MI rats pretreated with vehicle (0.1 ml/min, n 5 9 and n 5 7,
respectively), irbesartan (100 mg zkg21 zmin21, n 5 8 and n 5 7,
respectively), or PD123319 (20 mg zkg21 zmin21, n 5 8 and n 5 7,
respectively). Values are means 6 SE. *P , 0.05 vs. baseline; †P ,
0.05 vs. vehicle.
Fig. 2. Baseline regional myocardial blood flow values in sham-
operated (n 5 9) and MI rats (n 5 7). Myocardium represents the
sum of interventricular septum, left and right ventricles, and atria.
Values are means 6 SE. *P , 0.05 vs. sham.
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than the heart, including the kidney, at least at 3–4 wk
after coronary ligation, i.e., at the compensated stage of
cardiac remodeling (30).
Our in vivo data showing no AT2 receptor-mediated
vasodilation in the rat kidney contrast with in vitro
data demonstrating AT2 receptor-dependent vasodila-
tion in microperfused rabbit glomerular afferent and
efferent arterioles (1). One explanation for this discrep-
ancy might be a difference in shunting in the kidney
compared with the heart as a consequence of the use of
microspheres of a single size (15.5 mm in the present
study). However, we (29) demonstrated earlier that for
the measurement of regional blood flow, for the vast
majority of tissues (including the kidney), it does not
matter whether one uses microspheres of 10, 15, 25 or
35 mm in diameter (29). It is also unlikely that drawing
the reference blood sample from a relatively distal
vessel such as the femoral artery and/or non-appropri-
ate admixture of microspheres with blood after their
injection into the left ventricle underlie this phenome-
non. First, although using femoral arterial blood as a
reference may result in a modest overestimation of CO
(14), this will not affect regional blood flow or mask
regional AT2 receptor-mediated effects. Second, in this
study, as in many previous studies (6, 8, 10), we ob-
served similar blood flow values in the left and right
kidney both in sham-operated and infarcted animals
(data not shown), thereby supporting the concept of
appropriate admixture. A more likely explanation for
the lack of renal AT2 receptor-mediated vasodilation,
therefore, is that AT1 receptors predominate in renal
blood vessels other than the glomerular arterioles.
Indeed, our results obtained in the whole kidney do not
rule out the possibility of regional hemodynamic
changes with no change in total renal hemodynamic
blood flow.
The MI model used in the present study is well
established (30) and results in extensive transmural
infarction comprising .20% of the left ventricle. As a
consequence, and in full agreement with previous stud-
ies (16), baseline left ventricular blood flow was found
to be reduced by 35% in MI animals compared with
sham-operated animals. No flow reductions were ob-
served in other parts of the heart. The ANG II-induced
effects on myocardial vascular conductance were lim-
ited to the left ventricle in sham-operated animals and
to the right ventricle and viable left ventricle in MI
animals, indicating that the MI-induced changes in AT
receptor density were most prominent in these areas of
the heart. Such changes, which need to be confirmed in
future studies, most likely relate to the vascular
growth and remodeling processes that occur in the
noninfarcted myocardium (15, 16, 18, 24).
ANG II reduced systemic vascular conductance sim-
ilarly in sham-operated and MI rats. However, in MI
rats, this increase in systemic vascular conductance
was accompanied by a reduction in CO, thereby atten-
uating the rise in blood pressure in these rats.
In conclusion, this study is the first to demonstrate
the counteracting effect of AT2 receptors on AT1 recep-
tor-mediated coronary vasoconstriction. This effect ap-
pears to be enhanced after MI and parallels similar
findings on AT2 receptor-mediated growth inhibition
opposing AT1 receptor-mediated growth stimulation
(33, 39, 45).
Table 1. Regional myocardial conductances during 10-min intravenous infusions of ANG II in sham-operated
and MI rats pretreated with vehicle, irbesartan, or PD123319
Sham-Operated Rats, ng ANG zkg21 zmin21 MI Rats, ng ANG zkg21 zmin21
0 100 300 0 100 300
Interventricular Septum
Vehicle 4565 4463 4863 3464 3364 3763
Irbesartan 3865 4363 4664 44610 4766 5667
PD123319 3866 3364 3363 3362 3765 4066
Right ventricle
Vehicle 4767 4966 5266 3463 3964 4266
Irbesartan 48613 48610 4768 4264 4564 5463*
PD123319 5266 4265* 4466 4565 49610 4969
Left ventricle
Viable tissue
Vehicle 4765 4363 5563 3262 3363 3463
Irbesartan 4462 4965 5365 3664 4063 4864*
PD123319 4166 3462† 3562† 3463 3866 3865
Infarct area
Vehicle 1163 1163 962
Irbesartan 1364 1364 1663
PD123319 1163 1466 1063
Atria
Vehicle 1261 1061 1061 1663 1362 1361
Irbesartan 1563 1563 1462 1463 1462 1663
PD123319 1163 962 1063 1563 1364 1163
Values are means 6 SE; n 5 9 sham-operated and 7 myocardial infarcted (MI) rats pretreated with vehicle (0.1 ml/min), 8 sham-operated
and 7 MI rats pretreated with irbesartan (100 mg zkg21 zmin21), and 8 sham-operated and 7 MI rats pretreated with PD123319 (20
mg zkg21 zmin21). Values of myocardial conductance are in ml zmin21 zmmHg21 per g. *P , 0.05 vs. baseline; †P , 0.05 vs. vehicle.
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